Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis.
RA
disability
epidemiology
outcomes research
psychology
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
28 11 2022
28 11 2022
Historique:
received:
07
01
2022
accepted:
25
02
2022
pubmed:
12
3
2022
medline:
2
12
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
To identify groups of people with RA with different disability trajectories over 10 years, despite comparable levels of inflammation. Data for this analysis came from three European prospective cohort studies of people with RA [Norfolk Arthritis Register (NOAR), Early RA Network (ERAN), Étude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR)]. Participants were assessed regularly over 8 (ERAN) to 10 (NOAR/ESPOIR) years. Inclusion criteria were: recruited after 1 January 2000, <24 months baseline symptom duration, and disability (HAQ) and inflammation [two-component DAS28 (DAS28-2C)] recorded at baseline and at one other follow-up. People in each cohort also completed patient-reported outcome measures at each assessment (pain, fatigue, depressive symptoms). Group-based trajectory models were used to identify distinct groups of people with similar HAQ and DAS28-2C trajectories over follow-up. This analysis included 2500 people with RA (NOAR: 1000, ESPOIR: 766, ERAN: 734). ESPOIR included more women and the participants were younger [mean (standard deviation) age: NOAR: 57.1 (14.6), ESPOIR: 47.6 (12.5), ERAN: 56.8 (13.8); women: NOAR: 63.9%, ESPOIR: 76.9%, ERAN: 69.1%). Within each cohort, two pairs of trajectories following the hypothesized pattern (comparable DAS28-2Cs but different HAQs) were identified. Higher pain, fatigue and depressive symptoms were associated with increased odds of being in the high HAQ trajectories. Excess disability is persistent in RA. Controlling inflammation may not be sufficient to alleviate disability in all people with RA, and effective pain, fatigue and mood management may be needed in some groups to improve long-term function.
Identifiants
pubmed: 35274696
pii: 6547046
doi: 10.1093/rheumatology/keac137
pmc: PMC9707289
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4687-4701Subventions
Organisme : Versus Arthritis
ID : 21229
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 21755
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Références
J Rheumatol. 1996 Jan;23(1):52-60
pubmed: 8838508
Arthritis Rheum. 2003 Oct;48(10):2750-62
pubmed: 14558079
Semin Arthritis Rheum. 2020 Apr;50(2):209-219
pubmed: 31521376
J Epidemiol Community Health. 1999 Jan;53(1):46-50
pubmed: 10326053
Arthritis Care Res (Hoboken). 2014 Sep;66(9):1319-27
pubmed: 24470178
J Rheumatol. 2016 Jul;43(7):1292-9
pubmed: 27252420
Rheumatology (Oxford). 2020 Oct 1;59(10):2908-2919
pubmed: 32097471
Arthritis Rheumatol. 2017 Aug;69(8):1566-1575
pubmed: 28425173
Musculoskeletal Care. 2004;2(4):240-4
pubmed: 17041987
J Pain. 2019 Jun;20(6):716-727
pubmed: 30658176
RMD Open. 2020 Apr;6(1):
pubmed: 32371432
Arthritis Rheumatol. 2018 Sep;70(9):1377-1391
pubmed: 29873196
Br J Rheumatol. 1994 Aug;33(8):735-9
pubmed: 8055200
Rheumatology (Oxford). 2013 Nov;52(11):2016-24
pubmed: 23934221
Arthritis Care Res (Hoboken). 2015 Mar;67(3):340-8
pubmed: 25186552
Semin Arthritis Rheum. 2018 Dec;48(3):384-398
pubmed: 29680162
Ann Rheum Dis. 2006 Jun;65(6):763-9
pubmed: 16249225
Rev Rhum Mal Osteoartic. 1991 Jun;58(6):459-65
pubmed: 1896787
Rheumatology (Oxford). 2006 Apr;45(4):454-8
pubmed: 16287925
Arthritis Res Ther. 2021 Jun 14;23(1):169
pubmed: 34127054
Arthritis Res Ther. 2008;10(5):R106
pubmed: 18771585
Ann Rheum Dis. 2010 Mar;69(3):536-41
pubmed: 19825848
Arthritis Rheumatol. 2014 Apr;66(4):794-802
pubmed: 24757132
Arthritis Rheumatol. 2014 Aug;66(8):2006-14
pubmed: 24782222
Nat Rev Dis Primers. 2018 Feb 08;4:18001
pubmed: 29417936
Lancet. 1987 May 16;1(8542):1108-11
pubmed: 2883443
Arthritis Rheum. 2006 Sep;54(9):2784-92
pubmed: 16947781
N Engl J Med. 2004 May 20;350(21):2167-79
pubmed: 15152062
Arthritis Rheum. 1992 Jan;35(1):1-10
pubmed: 1731806
Curr Opin Rheumatol. 2017 May;29(3):269-276
pubmed: 28207494
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):94-101
pubmed: 28967354
J Rheumatol. 2018 Jun;45(6):766-770
pubmed: 29496893
Rheumatology (Oxford). 2019 Mar 01;:
pubmed: 30824919
Rheumatology (Oxford). 2015 Jan;54(1):83-90
pubmed: 25065011
Ann Rheum Dis. 2018 Jun;77(6):848-854
pubmed: 29475855
J Rheumatol. 2015 Nov;42(11):2059-65
pubmed: 26472420
Rheumatology (Oxford). 2020 Sep 1;59(9):2381-2391
pubmed: 31899521
Arthritis Care Res (Hoboken). 2015 May;67(6):865-72
pubmed: 25186344
Joint Bone Spine. 2007 Oct;74(5):440-5
pubmed: 17905631
Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S179-85
pubmed: 14969073
Br J Rheumatol. 1986 May;25(2):206-9
pubmed: 3708236